PF-07328948

Phase 1Small molecule

Pfizer

PF-07328948 is one of 89 small molecule programs targeting Hepatic Impairment. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic ImpairmentRecruiting

AdultCompleted

FunctionRecruiting

Hepatic ImpairmentPhase 1

Recruiting

AdultPhase 1

Completed

FunctionPhase 1

Recruiting

Competition

Competitive Landscape

120 competitors in Adult

#DrugCompanyPhaseTrials

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 2

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 2

1 4

Rifampicin

Boehringer Ingelheim

Phase 3

3 5

Opzelura

DDizal Pharmaceuticals

Phase 2

1 6

Skyclarys

Biogen

Phase 1

3 7

Sunlenca

Gilead

Phase 1

1 8

NM8074

NNovelMed Therapeutics

Phase 2

2 9

Lupron

Sun Pharmaceutical Industries, Inc.

Preclinical

1 10

Emtriva

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Hepatic Impairment

NCT07269301

Phase 1Recruiting

Function

NCT07315360

Clinical

Trials by Indication[1]

Adult3 trials

A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT07455240·10 enrolled

A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT06837259·26 enrolled

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT05807490·86 enrolled

Function1 trial

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07315360·28 enrolled

Single Dose1 trial

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT05654181·20 enrolled

Hepatic Impairment1 trial

A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-07328948 IN ADULTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIRMENT

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07269301·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PF-07328948. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-07328948 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-07328948. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

PF-07328948

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Adult3 trials

Function1 trial

Single Dose1 trial

Hepatic Impairment1 trial

References

Drug Info

Quick Facts

Related News